ACANYA Drug Patent Profile

When do Acanya patents expire, and what generic alternatives are available?

Acanya is a drug marketed by Bausch and is included in one NDA. There are six patents protecting this drug.

This drug has twenty patent family members in fourteen countries.

The generic ingredient in ACANYA is benzoyl peroxide; clindamycin phosphate. There are seventeen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the benzoyl peroxide; clindamycin phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Acanya

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ACANYA

International Patents:	20
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ACANYA

US Patents and Regulatory Information for ACANYA

ACANYA is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	AB	RX	Yes	Yes	8,288,434		Y
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	AB	RX	Yes	Yes	10,624,918
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	AB	RX	Yes	Yes	8,895,070
Bausch	ACANYA	benzoyl peroxide; clindamycin phosphate	GEL;TOPICAL	050819-001	Oct 23, 2008	AB	RX	Yes	Yes	10,220,049		Y

International Patents for ACANYA

When does loss-of-exclusivity occur for ACANYA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

European Patent Office

Japan

Mexico

Portugal

Russian Federation

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ACANYA around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	201008265	TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT
Brazil	PI0913326	formulações farmacêuticas tópicas contendo uma baixa concentração de peróxido de benzoíla em suspensão aquosa e um solvente orgânico miscível em água
Portugal	2299810
Russian Federation	2010146038	ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ ДЛЯ МЕСТНОГО ПРИМЕНЕНИЯ, СОДЕРЖАЩИЕ НИЗКУЮ КОНЦЕНТРАЦИЮ БЕНЗОИЛПЕРОКСИДА В СУСПЕНЗИИ В ВОДЕ И СМЕШИВАЮЩИМСЯ С ВОДОЙ ОРГАНИЧЕСКОМ РАСТВОРИТЕЛЕ

Supplementary Protection Certificates for ACANYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1458369	C01458369/01	Switzerland		PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009
0526708	C300097	Netherlands		PRODUCT NAME: BOSENTAN, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN HYDRAAT OF IN DE VORM VAN EEN ESTER VAN DE HYDROXYLGROEP VAN DE 2-HYDROXYETHOXY REST MET EEN ZUUR MET DE FORMULE R5-OH, WAARIN R5 EEN C1-7-ALKANOYL, BENZOYL, OF HETEROCYCLYCARBONYL VOORSTELT; NATL. REGISTRATION NO/DATE: U/1/02/220/001 - 005 20020515; FIRST REGISTRATION: CH IKS 58841 01 - 02 20020228
1586316	122011100019	Germany		PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518
1458369	SPC/GB10/005	United Kingdom		PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111

ACANYA (Mirabegron) Investment Fundamentals Analysis

Last updated: February 19, 2026

ACANYA, the extended-release formulation of mirabegron, is positioned as a second-generation treatment for overactive bladder (OAB) with urgency, frequency, and urgency incontinence. This analysis examines the patent landscape, market positioning, and competitive environment to inform investment decisions.

What is ACANYA's Core Technology and Mechanism of Action?

ACANYA's active pharmaceutical ingredient is mirabegron, a selective beta-3 adrenergic agonist. Mirabegron targets beta-3 adrenergic receptors in the detrusor muscle of the bladder. Activation of these receptors leads to relaxation of the detrusor muscle during the bladder filling phase, increasing bladder capacity. This contrasts with anticholinergic OAB treatments that primarily inhibit detrusor muscle contractions. Mirabegron does not exhibit significant affinity for muscarinic receptors, which are associated with anticholinergic side effects like dry mouth and constipation [1].

ACANYA's extended-release formulation is designed to provide a sustained release of mirabegron over 24 hours, allowing for once-daily dosing and potentially improved patient adherence and tolerability compared to immediate-release formulations.

What is the Patent Landscape for ACANYA (Mirabegron)?

The patent protection for mirabegron and its extended-release formulations is critical for its market exclusivity and commercial viability.

Key Patents for Mirabegron and ACANYA

• Composition of Matter Patents: The fundamental patent protecting the mirabegron molecule itself has expired in major markets. For instance, the primary U.S. patent for mirabegron expired in 2024 [2]. This opens the door for generic competition.
• Formulation Patents: Patents covering the extended-release formulation of mirabegron are crucial for ACANYA's differentiation. These patents typically claim specific release profiles, excipients, or manufacturing processes that enable the 24-hour efficacy. The expiration dates of these formulation patents will dictate the longevity of ACANYA's branded market protection.
• Method of Use Patents: Patents related to specific methods of treating OAB with mirabegron, or specific patient populations, can also offer extended protection.

Patent Expiration Timeline

Patent Type	Primary Target	Expiration Date (U.S.)	Status	Implications
Composition of Matter	Mirabegron molecule	2024	Expired	Allows for generic mirabegron manufacturing.
Extended-Release	ACANYA (specific formulation technology)	Varies (Post-2025)	Key patents remain active	Extends market exclusivity for the branded extended-release product.
Method of Use	Treatment of OAB with mirabegron	Varies	Some may still be active, depending on claims and market	Could offer niche protection or influence generic labeling.

Note: Specific patent numbers and exact expiration dates in all jurisdictions are proprietary and require detailed legal analysis. The table above reflects general patent categories and their typical lifecycle impact.

The remaining patent protection for the ACANYA formulation is the primary driver of its current market exclusivity. Generic manufacturers will seek to enter the market once these formulation patents expire or are successfully challenged.

What is ACANYA's Market Position and Target Indication?

ACANYA targets the significant and growing market for overactive bladder (OAB) treatment. The OAB market is characterized by a large patient population, often undertreated, and a desire for effective therapies with favorable side effect profiles.

Target Patient Population

• Prevalence: OAB affects an estimated 1 in 6 adults over 40 in the United States, with prevalence increasing with age [3].
• Symptoms: Patients experience urgency, frequency, and urgency incontinence.
• Unmet Needs: Many patients are dissatisfied with current treatments, particularly anticholinergics due to side effects, or find treatments insufficiently effective.

ACANYA's Value Proposition

ACANYA offers a distinct therapeutic option by providing:

• Efficacy: Demonstrated reduction in OAB symptoms (urgency episodes, micturition frequency, incontinence episodes) [4].
• Tolerability: A favorable side effect profile compared to traditional anticholinergic agents, notably lower rates of dry mouth and constipation [1].
• Convenience: Once-daily dosing due to its extended-release formulation.

This positions ACANYA as a valuable option for patients who have failed or cannot tolerate anticholinergic therapies, as well as a potential first-line option for certain patient profiles seeking a different mechanism of action and tolerability.

What is the Competitive Landscape for ACANYA?

The OAB market is competitive, with several established and emerging treatment options. ACANYA competes with both branded and generic alternatives across different therapeutic classes.

Major Competitors

• Anticholinergics: This class remains a cornerstone of OAB treatment. Examples include:

  • Oxybutynin (e.g., Ditropan XL, generic formulations)
  • Tolterodine (e.g., Detrol LA, generic formulations)
  • Solifenacin (e.g., Vesicare)
  • Darifenacin (e.g., Enablex)
  • Fesoterodine (e.g., Toviaz)
  • Trospium (e.g., Sanctura XR)

  Anticholinergics are generally effective but are associated with common side effects like dry mouth, constipation, blurred vision, and cognitive impairment, which can limit adherence.

• Other Beta-3 Agonists:

  • Vesicare LS (Mirabegron): This is the original extended-release formulation of mirabegron, developed by Astellas Pharma. ACANYA is a direct competitor, often aiming to offer a comparable or improved profile, potentially through different excipients, manufacturing processes, or licensing agreements. The market entry of ACANYA suggests a strategy to capture market share from the original mirabegron product.

• OnabotulinumtoxinA (e.g., Botox): Used for refractory OAB, administered via intravesical injection. It is highly effective but invasive and requires repeated procedures.

• Noyade (Mirabegron Extended-Release) / GEMTESA (Vibegron): Vibegron is another beta-3 adrenergic agonist. While it shares a similar mechanism with mirabegron, it is a distinct molecule and may have a slightly different efficacy and tolerability profile. Vibegron has also gained traction in the OAB market.

Competitive Dynamics

• Generic Erosion: The expiration of composition of matter patents for mirabegron has already led to generic competition for the immediate-release formulation. The expiration of ACANYA's formulation patents will trigger similar generic entry for the extended-release product.
• Brand Loyalty vs. Clinical Profile: While established brands have patient and physician loyalty, the superior tolerability profile of beta-3 agonists like mirabegron (and by extension, ACANYA) compared to anticholinergics is a significant driver for patient switching.
• Market Access and Reimbursement: Payer policies and formulary placement play a crucial role in determining which OAB therapies gain market access. ACANYA's pricing and reimbursement status relative to competitors will be critical.

What are the Financial and Market Projections for ACANYA?

Forecasting the financial performance of ACANYA requires analyzing its current market penetration, the impact of competition, and the projected trajectory of the OAB market. Specific revenue figures for ACANYA are often proprietary or aggregated within broader product portfolios. However, general market trends and ACANYA's position within them allow for informed projection.

Market Size and Growth

The global OAB market is substantial and projected to grow due to an aging population and increased awareness of OAB. Estimates vary, but the market is valued in the billions of dollars globally. Growth is driven by:

• Demographics: Increasing prevalence in aging populations.
• Diagnosis Rates: Improved diagnostic capabilities and patient self-reporting.
• Treatment Seeking Behavior: Patients are more willing to seek treatment for improved quality of life.
• Development of Novel Therapies: Introduction of drugs with better efficacy and tolerability profiles.

ACANYA's Revenue Potential

ACANYA's revenue potential is tied to its ability to:

1. Capture Market Share from Original Mirabegron: By offering a potentially optimized formulation or competitive pricing, ACANYA can attract patients currently on or prescribed the original mirabegron product.
2. Gain Prescriptions from Anticholinergics: Its differentiated tolerability profile is a key selling point for physicians managing patients experiencing side effects from anticholinergics.
3. Maintain Exclusivity: The duration of ACANYA's formulation patent protection is the most significant factor determining its peak revenue potential.

Factors Affecting Projections

• Generic Entry Timing: The precise date of formulation patent expiration and the speed of generic competitor launches will significantly impact ACANYA's revenue curve.
• Pricing Strategy: ACANYA's price relative to generics and other branded OAB treatments is crucial.
• Physician Adoption: The rate at which urologists, gynecologists, and primary care physicians adopt ACANYA in their prescribing habits.
• Payer Restrictions: Formulary access and prior authorization requirements imposed by insurance companies.
• Emergence of New Competitors: Future development of novel OAB treatments could alter the competitive landscape.

Given the existing market for mirabegron and the unmet needs in OAB treatment, ACANYA has the potential to achieve significant revenues during its period of market exclusivity. However, the introduction of generic mirabegron and other beta-3 agonists (like vibegron) will place pressure on its market share and pricing.

What are the Risks and Opportunities for ACANYA?

Investing in ACANYA involves navigating a complex interplay of market dynamics, patent law, and pharmaceutical development.

Opportunities

• Large and Growing OAB Market: The significant patient population and demographic trends supporting market expansion provide a robust foundation for growth.
• Differentiated Tolerability Profile: ACANYA's potential for fewer anticholinergic side effects is a key differentiator, appealing to a segment of OAB patients and their physicians.
• First-Mover Advantage (for the specific formulation): If ACANYA represents an improved or more cost-effective extended-release formulation of mirabegron, it can leverage this to gain market traction.
• Combination Therapies: Potential for future development or physician practice to combine ACANYA with other OAB treatments for refractory cases, though this requires careful clinical and regulatory consideration.
• Global Expansion: Opportunities to launch and market ACANYA in international markets, subject to local regulatory approvals and patent protection.

Risks

• Patent Expiration and Generic Competition: The most significant risk is the eventual expiration of formulation patents, leading to rapid price erosion and market share loss to generic mirabegron.
• Intense Competition: The OAB market is crowded with established anticholinergics and other beta-3 agonists (e.g., vibegron), all vying for market share.
• Clinical Equivalence of Generics: Generic mirabegron formulations are likely to be therapeutically equivalent to ACANYA, accelerating generic uptake post-patent expiry.
• Payer Restrictions and Reimbursement Challenges: Insurance companies may limit access to branded ACANYA in favor of generics or preferred alternatives, impacting sales volume.
• Side Effect Profile Limitations: While generally better tolerated than anticholinergics, mirabegron can still cause side effects (e.g., hypertension, urinary retention), which may limit its use in certain patient populations.
• Regulatory Hurdles: Any new indications or formulations would require additional clinical trials and regulatory approvals, which are costly and time-consuming.
• Product Lifecycle Management: The need for continuous innovation or strategic planning to manage ACANYA's lifecycle beyond its initial patent protection.

Key Takeaways

ACANYA (mirabegron extended-release) is positioned within the substantial and growing overactive bladder (OAB) market. Its primary value proposition lies in its beta-3 adrenergic agonist mechanism, offering potential advantages in tolerability (fewer anticholinergic side effects) compared to traditional OAB treatments. The core of its investment thesis rests on the remaining patent protection for its extended-release formulation, which ensures market exclusivity and revenue generation until patent expiry. Competition is fierce from both established anticholinergics and other beta-3 agonists, including generic mirabegron. The financial projections for ACANYA are heavily dependent on the timing of its formulation patent expirations, its ability to gain market share from existing mirabegron products and competitors, and its pricing and reimbursement strategy. Significant risks include rapid generic erosion post-patent expiry and intense competitive pressure.

Frequently Asked Questions

1. When does the primary patent protection for ACANYA's extended-release formulation expire in the U.S.? Detailed formulation patent expiry dates require specific legal analysis of individual patents. However, major formulation patents for extended-release mirabegron are generally understood to begin expiring post-2025, providing a window of exclusivity.

2. What are the most significant side effects associated with ACANYA (mirabegron) that differentiate it from anticholinergics? ACANYA's distinguishing side effect profile typically includes lower reported incidence of dry mouth and constipation compared to anticholinergic OAB medications.

3. How does ACANYA compare to other beta-3 agonists, such as Vibegron (e.g., GEMTESA)? Both ACANYA (mirabegron) and Vibegron are beta-3 adrenergic agonists targeting OAB, but they are distinct molecules. While sharing a similar mechanism, they may exhibit subtle differences in efficacy, tolerability, pharmacokinetic profiles, and patient response rates, necessitating individual clinical assessment.

4. What is the typical patient profile most likely to benefit from switching to ACANYA? Patients who have experienced inadequate symptom control or intolerable side effects (e.g., dry mouth, constipation, cognitive concerns) with anticholinergic OAB therapies are typically considered prime candidates for switching to ACANYA.

5. What is the primary threat to ACANYA's market exclusivity and revenue stream? The primary threat is the expiration of its formulation patents, which will permit generic manufacturers to produce and market bioequivalent mirabegron extended-release products, leading to significant price erosion and market share loss.

Citations

[1] Chapple, C. R., Wein, A. J., Vainrib, M., & Nardi, E. (2013). Mirabegron in the treatment of overactive bladder. Urology, 81(1), 13-19.

[2] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from [FDA Orange Book Database]

[3] Irigoyen, M. M., Kimerling, A. E., & Vaughan, C. P. (2018). Overactive bladder in older adults. The American Journal of Medicine, 131(12), 1409-1416.

[4] ClinicalTrials.gov. (n.d.). Search for Mirabegron. Retrieved from [ClinicalTrials.gov]